Works matching DE "VENETOCLAX"

Results: 568
    1
    2

    VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.

    Published in:
    Annals of Hematology, 2025, v. 104, n. 7, p. 3647, doi. 10.1007/s00277-025-06496-7
    By:
    • Kretschmer, Lydia;
    • Ruhnke, Leo;
    • Schliemann, Christoph;
    • Fransecky, Lars;
    • Steffen, Björn;
    • Kaufmann, Martin;
    • Burchert, Andreas;
    • Schmid, Christoph;
    • Hanoun, Maher;
    • Sauer, Tim;
    • Metzeler, Klaus H.;
    • Schäfer-Eckart, Kerstin;
    • Hänel, Mathias;
    • Crysandt, Martina;
    • Jäger, Paul;
    • Krause, Stefan W.;
    • Dierks, Christine;
    • Klein, Stefan;
    • Maguire, Nadia;
    • Frenzel, Lukas P.
    Publication type:
    Article
    3
    4
    5
    6

    Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 5513, doi. 10.1007/s00432-022-04473-5
    By:
    • Pan, Guangchao;
    • Zhong, Mengya;
    • Yao, Jingwei;
    • Tan, Jinshui;
    • Zheng, Huijian;
    • Jiang, Yuelong;
    • Tang, Yuanfang;
    • Zhou, Hui;
    • Qin, Dongmei;
    • Yu, Xingxing;
    • Liu, Long;
    • Li, Zhifeng;
    • Lin, Zhijuan;
    • Jiang, Yirong;
    • Xu, Bing;
    • Zha, Jie
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1<sup>+</sup>TIM3<sup>+</sup> exhausted CD8<sup>+</sup> T cells.

    Published in:
    Frontiers in Immunology, 2024, p. 01, doi. 10.3389/fimmu.2024.1386517
    By:
    • Corradi, Giulia;
    • Forte, Dorian;
    • Cristiano, Gianluca;
    • Polimeno, Andrea;
    • Ciciarello, Marilena;
    • Salvestrini, Valentina;
    • Bandini, Lorenza;
    • Robustelli, Valentina;
    • Ottaviani, Emanuela;
    • Cavo, Michele;
    • Ocadlikova, Darina;
    • Curti, Antonio
    Publication type:
    Article
    24
    25
    26

    Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia.

    Published in:
    Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-53535-4
    By:
    • Wegmann, Rebekka;
    • Bonilla, Ximena;
    • Casanova, Ruben;
    • Chevrier, Stéphane;
    • Coelho, Ricardo;
    • Esposito, Cinzia;
    • Ficek-Pascual, Joanna;
    • Goetze, Sandra;
    • Gut, Gabriele;
    • Jacob, Francis;
    • Jacobs, Andrea;
    • Kuipers, Jack;
    • Lischetti, Ulrike;
    • Mena, Julien;
    • Milani, Emanuela S.;
    • Prummer, Michael;
    • Del Castillo, Jacobo Sarabia;
    • Singer, Franziska;
    • Sivapatham, Sujana;
    • Toussaint, Nora C.
    Publication type:
    Article
    27

    ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress.

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2025, v. 44, n. 1, p. 1, doi. 10.1186/s13046-024-03267-6
    By:
    • Carter, Jenna L.;
    • Su, Yongwei;
    • Al-Antary, Eman T.;
    • Zhao, Jianlei;
    • Qiao, Xinan;
    • Wang, Guan;
    • Edwards, Holly;
    • Polin, Lisa;
    • Kushner, Juiwanna;
    • Dzinic, Sijana H.;
    • White, Kathryn;
    • Buck, Steven A.;
    • Hüttemann, Maik;
    • Allen, Joshua E.;
    • Prabhu, Varun V.;
    • Yang, Jay;
    • Taub, Jeffrey W.;
    • Ge, Yubin
    Publication type:
    Article
    28

    Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia.

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2024, v. 43, n. 1, p. 1, doi. 10.1186/s13046-024-03100-0
    By:
    • Ren, Jun;
    • Huang, Junpeng;
    • Yang, Zailin;
    • Sun, Minghui;
    • Yang, Jing;
    • Lin, Can;
    • Jin, Fangfang;
    • Liu, Yongcan;
    • Tang, Lisha;
    • Hu, Jiayuan;
    • Wei, Xingyu;
    • Chen, Xinyi;
    • Yuan, Zihao;
    • Yang, Zesong;
    • Chen, Yanmeng;
    • Zhang, Ling
    Publication type:
    Article
    29
    30
    31
    32
    33
    34

    Combined ibrutinib and venetoclax for treatment of patients with ibrutinib‐resistant or double‐refractory chronic lymphocytic leukaemia.

    Published in:
    British Journal of Haematology, 2022, v. 199, n. 2, p. 239, doi. 10.1111/bjh.18357
    By:
    • Hampel, Paul J.;
    • Rabe, Kari G.;
    • Call, Timothy G.;
    • Ding, Wei;
    • Leis, Jose F.;
    • Kenderian, Saad S.;
    • Muchtar, Eli;
    • Wang, Yucai;
    • Koehler, Amber B.;
    • Parrondo, Ricardo;
    • Schwager, Susan M.;
    • Shi, Min;
    • Braggio, Esteban;
    • Slager, Susan L.;
    • Kay, Neil E.;
    • Parikh, Sameer A.
    Publication type:
    Article
    35
    36
    37
    38

    Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.

    Published in:
    British Journal of Haematology, 2022, v. 197, n. 1, p. 63, doi. 10.1111/bjh.18051
    By:
    • On, Sandy;
    • Rath, Carolyn G.;
    • Lan, Michelle;
    • Wu, Bobby;
    • Lau, Kimberly M.;
    • Cheung, Edna;
    • Alegria, William;
    • Young, Rebecca;
    • Tan, Marisela;
    • Kim, Carrie;
    • Phun, Jennifer;
    • Patel, Nimish;
    • Mannis, Gabriel;
    • Logan, Aaron C.;
    • Kennedy, Vanessa;
    • Goodman, Aaron;
    • Taplitz, Randy A.;
    • Young, Patricia A.;
    • Wen, Raymond;
    • Saunders, Ila M.
    Publication type:
    Article
    39

    Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2022, v. 196, n. 6, p. e71, doi. 10.1111/bjh.17996
    By:
    • Salhotra, Amandeep;
    • Tsai, Ni‐Chun;
    • Zhang, Jianying;
    • Ngo, Dat;
    • Aribi, Ahmed;
    • Sandhu, Karamjeet;
    • Ball, Brian;
    • Al‐Malki, Monzr;
    • Ali, Haris;
    • Koller, Paul;
    • Artz, Andrew;
    • Forman, Stephen;
    • Nakamura, Ryotaro;
    • Stein, Anthony;
    • Marcucci, Guido;
    • Aldoss, Ibrahim;
    • Pullarkat, Vinod
    Publication type:
    Article
    40
    41
    42
    43
    44
    45

    Prescription patterns of venetoclax in acute myeloid leukemia.

    Published in:
    Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3298
    By:
    • Ucciero, Andrealuna;
    • Traversa, Giuseppe;
    • Pisterna, Alessia;
    • Cardinali, Valeria;
    • Sciabolacci, Sofia;
    • Poloni, Antonella;
    • Capelli, Debora;
    • Gaidano, Gianluca;
    • Patriarca, Andrea;
    • Lunghi, Monia
    Publication type:
    Article
    46
    47

    A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.

    Published in:
    Hematological Oncology, 2024, v. 42, n. 3, p. 1, doi. 10.1002/hon.3274
    By:
    • Manda, Sudhir;
    • Anz, Bertrand M.;
    • Benton, Christopher;
    • Broun, E. Randolph;
    • Yimer, Habte A.;
    • Renshaw, John S.;
    • Geils, George;
    • Berdeja, Jesus;
    • Cruz, Jose;
    • Melear, Jason M.;
    • Fanning, Suzanne;
    • Fletcher, Luke;
    • Li, Yukun;
    • Duan, Yinghui;
    • Werner, Michael E.;
    • Potluri, Jalaja;
    • Pai, Madhavi V.;
    • Donnellan, William B.
    Publication type:
    Article
    48
    49
    50